Larimar Therapeutics Inc (LRMR)
Insider transactions
A complete record of Form 4 filings tracking every share acquisition and disposal by executives, directors, and senior officers. Filterable by date range and transaction type, the table exposes the direct market actions of those with the deepest knowledge of a company's operations — providing a factual, data-driven signal of internal conviction that complements traditional fundamental and technical analysis.
Transaction date | Executive | Executive Title | Security Type | Acquisition / Disposal | Shares | Share price |
|---|---|---|---|---|---|---|
| Jul 6, 2026 | HAMILTON, THOMAS EDWARD | Director | Common Stock | Acquisition | 50,000 | 3.338 |
| May 19, 2026 | HAMILTON, THOMAS EDWARD | Director | Stock Option (Right to Buy) | Acquisition | 55,150 | 0 |
| May 19, 2026 | THOMAS, FRANK E | Director | Stock Option (Right to Buy) | Acquisition | 55,150 | 0 |
| May 19, 2026 | SHERMAN, JEFFREY W | Director | Stock Option (Right to Buy) | Acquisition | 55,150 | 0 |
| May 19, 2026 | TRUITT, JOSEPH | Director | Stock Option (Right to Buy) | Acquisition | 55,150 | 0 |
| May 19, 2026 | LEFF, JONATHAN S | Director | Stock Option (Right to Buy) | Acquisition | 55,150 | 0 |
| May 19, 2026 | FLYNN, JAMES E | Director, 10% Owner, * Director by Deputization | Stock Option (Right to Buy) | Acquisition | 55,150 | 0 |
| Feb 27, 2026 | FLYNN, JAMES E | Director, 10% Owner, * Director by Deputization | Common Stock | Acquisition | 1,084,012 | 5 |
| Feb 27, 2026 | FLYNN, JAMES E | Director, 10% Owner, * Director by Deputization | Common Stock | Acquisition | 2,000,000 | 5 |
| Feb 27, 2026 | FLYNN, JAMES E | Director, 10% Owner, * Director by Deputization | Common Stock | Acquisition | 1,084,010 | 5 |
| Feb 27, 2026 | FLYNN, JAMES E | Director, 10% Owner, * Director by Deputization | Common Stock | Acquisition | 831,978 | 5 |
| Feb 27, 2026 | SHERMAN, JEFFREY W | Director | Common Stock | Acquisition | 5,000 | 5 |
| Feb 27, 2026 | THOMAS, FRANK E | Director | Common Stock | Acquisition | 5,000 | 5 |
| Feb 27, 2026 | HAMILTON, THOMAS EDWARD | Director | Common Stock | Acquisition | 100,000 | 5 |
| Jan 26, 2026 | CLAYTON, RUSSELL | Chief Medical Officer | Stock Option (Right to Buy) | Acquisition | 153,822 | 0 |
| Jan 26, 2026 | CLAYTON, RUSSELL | Chief Medical Officer | Common Stock | Acquisition | 25,637 | 0 |
| Jan 26, 2026 | BEN-MAIMON, CAROLE | Director, President and CEO | Stock Option (Right to Buy) | Acquisition | 600,600 | 0 |
| Jan 26, 2026 | CELANO, MICHAEL | Chief Financial Officer | Common Stock | Acquisition | 37,604 | 0 |
| Jan 26, 2026 | SHANKAR, GOPI | Chief Development Officer | Common Stock | Acquisition | 25,637 | 0 |
| Jan 26, 2026 | SHANKAR, GOPI | Chief Development Officer | Stock Option (Right to Buy) | Acquisition | 153,822 | 0 |
| Jan 26, 2026 | CELANO, MICHAEL | Chief Financial Officer | Stock Option (Right to Buy) | Acquisition | 225,622 | 0 |
| Jan 26, 2026 | BEN-MAIMON, CAROLE | Director, President and CEO | Common Stock | Acquisition | 100,100 | 0 |